CST-3056 / CuraSen Therap - LARVOL DELTA

A Study in Subjects With Neurogenic Orthostatic Hypotension (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: CuraSen Therapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hypotension

A Study in Subjects With Neurogenic Orthostatic Hypotension (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: CuraSen Therapeutics, Inc. | Trial completion date: Mar 2026 ➔ Jun 2026

Trial completion date • Hypotension

A Study in Subjects With Neurogenic Orthostatic Hypotension (clinicaltrials.gov) - P2 | N=12 | Recruiting | Sponsor: CuraSen Therapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hypotension

A Study in Subjects With Neurogenic Orthostatic Hypotension (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: CuraSen Therapeutics, Inc.

New P2 trial • Hypotension

CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial (Businesswire) - "CuraSen Therapeutics, Inc...announced today that it has treated its first subject with CuraAX, an alpha-1A adrenoceptor agonist, in a Phase 1 clinical trial...The Phase 1 trial, whose objective is to assess the safety, tolerability and pharmacokinetics of CuraAX, will evaluate multiple dose levels of CuraAX in approximately 56 healthy volunteers, with an additional food effect cohort of six patients."

Trial status • CNS Disorders

CuraSen Therapeutics secures funding to advance CST-3056 for Alzheimer’s disease (Pharmaceutical Business Review (PBR)) - "Alzheimer's Drug Discovery Foundation co-founder and chief science officer Howard Fillit said: 'Alpha-1A adrenoceptors are known to help regulate neurotransmission and are prevalent in the areas of the brain important to memory and learning, making them a promising target for Alzheimer's drug development by offering potential neuroprotective benefits."

Media quote

CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease (Businesswire) - "CuraSen Therapeutics, Inc...announced that it has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease....CuraSen will commence non-clinical studies early in 2024 and expects to initiate Phase 1 clinical testing later that year."

Financing • New P1 trial • Alzheimer's Disease • CNS Disorders